Abstract: A unified mesh vertex indexing method for high-fidelity parallel full-core fast reactor simulation belongs to the fields of high performance computing and numerical simulation. Firstly, a constant is defined and a message passing interface (MPI) is initialized; processors then generate local hash tables concurrently to obtain local vertex numbers; next, a processor 0 generates a global hash table by MPI_Send( ) and MPI_Recv( ) functions, processes a conflict, and finally obtains global vertex numbers, thus building indexes. Local numbering and global numbering of mesh vertexes are realized with the hash table. Parallel processing of vertex numbering tasks of the processors is realized through the MPI. An innovative global vertex numbering method is provided for the processors. Large-scale parallel efficiency is improved. The research and development of large-scale high-fidelity numerical simulation software for a thermal fluid can be facilitated.

Abstract: Provided herein is an oral care composition comprising a basic amino acid or a salt thereof in an amount of from 0.001 weight % to 0.08 weight % by total weight of the composition, and an orally acceptable carrier. The composition is effective in accelerating HSP 27 production in damaged tissues of the oral cavity and enhances repair of the damaged tissue.

Abstract: Adapters are provided. An adapter includes at least one first sub-adapter. Each first sub-adapter includes: a first nucleotide single strand and a second nucleotide single strand, the first nucleotide single strand being complementarily paired with the second nucleotide single strand; and a first nucleotide single strand segment, the first nucleotide single strand segment being ligated to an end of the first nucleotide single strand or an end of the second nucleotide single strand. The first nucleotide single strand segment includes at least one random base and at least one adenine (A) base. Each random base is any one of an A base, a cytosine (C) base, a guanine (G) base and a thymine (T) base.

Abstract: The present invention discloses a non-linear PEGylated lipid, including the structure represented by the Formula (1); wherein, B1 and B2 are linking bonds or alkylene groups; L1 and L2 are linking bonds or divalent linking groups; Lx, Y, and Ld are divalent linking groups; R1 and R2 are C4-50 hydrocarbon groups or C4-50 residues of hydrocarbon derivative containing 1-4 heteroatoms; X is —CH< or n1, n2, and n3 are integers in the range of 4-250; T is a terminal group. Compared with linear PEGylated lipids, the non-linear PEGylated lipid provided herein can realize better protective effects toward the modified LNPs. The lipid pharmaceutical composition of the present invention exhibits high efficiency of drug encapsulation, appropriate particle size, non-toxicity, and good stability in serum. The LNP-nucleic acid pharmaceutical composition of the present invention demonstrates an excellent ability to complex with nucleic acids and shows high transfection activity.

Abstract: A non-linear PEGylated lipid of the Formula (1) contains a tertiary amine; wherein, B1 and B2 are linking bonds or alkylene groups; L1, L2, Ld, and Lx are linking bonds or divalent linking groups; R1 and R2 are C1-50 aliphatic hydrocarbon groups or C1-50 residues of aliphatic hydrocarbon derivatives, each containing 0-10 heteroatoms; y is 2 or 3; X is C or CH; XPEG is a polyethylene glycol component. Compared with linear PEGylated lipids, the PEGylated lipid can realize better surface modification of LNP, better protective effects, extended systemic circulation of LNP, and significantly reduced biological toxicity of LNP. The LNP pharmaceutical composition shows excellent drug delivery capabilities. The lipid-nucleic acid pharmaceutical composition and its formulation exhibit higher pharmaceutical efficacy, especially the LNP-nucleic acid pharmaceutical composition.

Abstract: A nitrogen-branched non-linear PEGylated lipid containing a tertiary amine, which is represented by the Formula (1); wherein, B1 and B2 are linking bonds or alkylene groups; L1, L2, Ld and Lx are linking bonds or divalent linking groups L; R1 and R2 are C1-50 aliphatic hydrocarbon groups or C1-50 residues of aliphatic hydrocarbon derivative, each containing 0-10 heteroatoms; Ncore is a multivalent group of valence y+1 and contains a trivalent nitrogen-atom branching core connected to Ld; y is 2, 3, 4, 5, 6, 7, 8, 9, or ?10; XPEG are polyethylene glycol components. Compared with linear PEGylated lipids, the nitrogen-branched PEGylated lipid herein can realize better surface modification of LNP. The present invention also provides a lipid pharmaceutical composition and its formulation containing the PEGylated lipid, which can enhance the targeting ability of drugs and improve the transfection efficiency of nucleic acid drugs.

Abstract: A nitrogen-branched non-linear PEGylated lipid of Formula (1), wherein, X is —CRa< or (Ra is H or a C1-12 alkyl group); B1 and B2 are linking bonds or C1-20 alkylene groups; L1 and L2 are linking bonds or divalent linking groups; R1 and R2 are C1-50 aliphatic hydrocarbon groups or C1-50 residues of aliphatic hydrocarbon derivative, each containing 0-10 heteroatoms; Ld is a linking bond or a divalent linking group; Ncore is a multivalent group of valence y+1, and contains a trivalent nitrogen-atom branching core connected to Ld; y is 2, 3, 4, 5, 6, 7, 8, 9, or ?10; Lx is a linking bond or a divalent linking group; XPEG is a polyethylene glycol component. The non-linear PEGylated lipid herein can realize better surface modification of LNP. The lipid nanoparticle pharmaceutical composition and its formulation exhibit higher drug efficacy, especially for nucleic acid drugs.

Abstract: Methods of identifying an individual as being a slow gingivitis responder or a high gingivitis responder are disclosed. Some methods are based on IL-1? levels in the individual's GCF at the site of inflammation. Some methods are based on MIF and/or CCL-1 levels in the individual's GCF in healthy tissue distant from the site of inflammation. Some disclosed methods are based on temporal differences in IL-8, IL-6 and/or TNF? levels in the individual's GCF in healthy tissue distant from the site of inflammation during the development of plaque induced inflammation. Methods of treating an individual who has gingivitis and methods of preventing gingivitis are also provided. The treatment and prevention methods comprise determining if individual is a slow gingivitis responder or a high gingivitis responder and applying oral care compositions to the individual's oral cavity.

Abstract: Oral care compositions and methods for treating, preventing, or inhibiting dry mouth and/or inflammation of the oral cavity or a surface thereof are disclosed. Oral care compositions for improving oral care by treating, preventing, or otherwise inhibiting discomfort, irritation, or gum pain of the oral cavity are also disclosed. The oral care composition may include an orally acceptable vehicle, hyaluronic acid, and one or more benefit agents. The method for treating, preventing, or inhibiting dry mouth and/or inflammation of the oral cavity or a surface thereof may include contacting the oral cavity or the surface thereof with the oral care compositions.

Abstract: A novel type of cationic lipid and PEGylated derivative thereof, a cationic liposome and a cationic liposome-nucleic acid pharmaceutical composition containing the cationic lipid and formulation thereof include an ionizable lipid compound of the general formula (1). This compound is slightly ionized or neutral at physiological pH but undergoes greater ionization under acidic conditions, exhibiting lower toxicity in the systemic circulation and improved endosomal escape ability. The compound's polar head contains an ionizable tertiary amine group along with a side chain containing functional groups, while the tail chains may include linking groups that are easily degraded. Cationic liposomes containing the compound have a better ability to complex with nucleic acid drugs, higher stability in serum, no apparent cytotoxicity, and high transfection efficiency.

Abstract: Provided are a class of alkylphenol compounds and a preparation method therefor. Specifically provided are a new alkyl polyphenol compound as represented by chemical formula I, and a preparation method therefor and the use thereof in the treatment of metabolic syndrome.

Abstract: A microfluidic flow channel structure and a microfluidic chip are described. The microfluidic flow channel structure includes a main chamber, wherein the main chamber includes at least two division zones and a reaction zone, and the at least two division zones are respectively connected with the reaction zone, wherein each division zone includes a first division wall, and the first division wall is provided with an opening for liquid inlet; a diversion structure is arranged at the opening of at least one division zone, and the diversion structure at least includes a first diversion wall, which is arranged opposite the first division wall; a first division channel is formed between the first diversion wall and the first division wall, and the first division channel includes at least two liquid outlets.

Abstract: A battery cell, a battery, and an electric device relating to the field of battery.

Abstract: The present disclosure discloses a high-safety ternary positive electrode material and a method for preparing the same; wherein the ternary positive electrode material has a chemical composition of Lia(NixCoyMn1-x-y)1-bMbO2-cAc, wherein 0.75?a?1.2, 0.75?x<1, 0<y?0.15, 1?x?y>0, 0?b?0.01, 0?c?0.2, M is one or more selected from the group consisting of Al, Zr, Ti, Y, Sr, W and Mg, and A is one or more selected from the group consisting of S, F and N; and CMn?(1?x?y)?0.07; CCo?y?0.05; 0?[CMn?(1?x?y)]/(CCo?y)?2.0. The ternary positive electrode material of the present disclosure is a high-nickel single crystal material with gradient concentration; it has the advantages of high capacity and high thermal stability, and the preparation method is simple, and is suitable for large-scale production.

Abstract: Methods of increasing sIgA levels in an individual's oral cavity are disclosed. The methods comprise applying effective amounts of zinc oxide, zinc citrate, and arginine Methods of increasing the concentration of sIgA in the individual's mucosa pellicle in the oral cavity are disclosed. Methods of increasing phagocytotic activity of phagocytotic cells in the individual's oral cavity are also disclosed. In addition, methods of increasing levels of ?-Defensin 1 in the individual's oral cavity are disclosed.

Abstract: The present invention relates to oral hydrogel compositions, more particularly to thermosensitive gel compositions, which undergo a sol-gel transition in the oral cavity, and which optionally comprise therapeutic actives for sustained release.

Abstract: The present disclosure belongs to the technical field of battery production and manufacturing, and specifically relates to a cylindrical battery and a battery module. The cylindrical battery includes: a housing, a cell and a top cover assembly. The housing is provided with an opening. The cell is arranged in the housing, the cell is provided with a first tab and a second tab opposite in polarity to the first tab, and the first tab and the second tab are both located on a same end face of the cell. The top cover assembly seals the opening and includes a cover, a first conductive portion and a second conductive portion. The cover, the first conductive portion and the second conductive portion are in insulating connection, the first conductive portion is connected with the first tab, and the second conductive portion is connected with the second tab.

Abstract: A detection method includes: determining process data of a new process; according to the process data of the new process, detecting, by a first production system, whether a wafer carrier type of the new process matches an acceptable level of a corresponding process step or not and whether the new process matches a flag of the corresponding process step or not; if not, determining that the process data does not pass the detection and outputting first detection information; or if the wafer carrier type of the new process matches the acceptable level of the corresponding process step and the new process matches the flag of the corresponding process step, detecting, by a second production system, if the second production system detects a mismatch, determining that the process data does not pass the detection and outputting second detection information.

Abstract: The disclosure relates to the technical field of battery production and manufacture, in particular to a cylindrical battery electrode plate including a electrode plate body and a plurality of tabs provided on one side of the electrode plate body, wherein a gap area is provided between adjacent tabs of the plurality of tabs, each of the plurality of tabs is respectively provided with one or more slits extending along a surface thereof, a starting end of each of the slits is provided at one end, away from the electrode plate body, the extending direction of each of the slits is arranged to form an included angle with the arrangement direction of the plurality of tabs, and each of the plurality of tabs is divided into a plurality of sub-tabs by the slits.

Abstract: Disclosed are a bare cell, a cylindrical battery and an assembly method of the bare cell. The bare cell is formed a cylinder by stacking and winding a first electrode plate, a separator and a second electrode plate, the polarity of the first electrode plate is opposite to the polarity of the second electrode plate, at least one of the first electrode plate and the second electrode plate forms a plurality of tabs at at least one end of the cylinder in an axial direction, each of the plurality of tabs is provided with at least one die-cutting line to form a plurality of sub-tabs, the plurality of tabs are bent and flattened in a radial direction, and the plurality of sub-tabs of two adjacent layers of the plurality of tabs are arranged in a staggered manner.